Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat

Digestive Diseases and Sciences

Volumn 46, Issue 10, 2001, Pages 2120-2126

  Deters, M ^a   Nolte, K ^a   Kirchner, G ^a   Resch, K ^a   Kaever, V ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cholestasis; Cyclosporin; Rat; Sirolimus; Tacrolimus

Indexed keywords

BILE SALT; CHOLESTEROL; CYCLOSPORIN A; GLUTATHIONE TRANSFERASE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; BILE DUCT FISTULA; BILE FLOW; BILIARY EXCRETION; CHOLESTASIS; CONTROLLED STUDY; DRUG EFFECT; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; BILE ACIDS AND SALTS; BILIARY FISTULA; BILIARY TRACT; CHOLESTASIS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; IMMUNOSUPPRESSIVE AGENTS; MALE; RATS; RATS, WISTAR; SIROLIMUS; TACROLIMUS;

EID: 0034788536     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011942310737     Document Type: Article

References (31)

1. Rapamune (sirolimus, rapamycin): An overview and mechanism of action
2. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK 506 complexes
3. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
4. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy
5. Nephrotoxicity of immunosuppressive drugs: Experimental and clinical observations
6. Prolongation of renal allograft in a large animal model by oral rapamycin monotherapy
7. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisolon-treated renal transplant patients
8. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial
9. Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A
10. Cholestasis caused by inhibition of the adenosine triphosphat-dependent bile salt transport in rat liver
11. High plasma cholesterol in drug-induced cholestasis is associated with enhanced hepatic cholesterol synthesis
12. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonist but produce extended graft survival in cardiac transplantation in the rat
13. Sirolimus-tacrolimus combination immunosuppression
14. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat
15. Influence of tacrolimus on bile acid and lipid composition in continuously drained bile using a rat model. Comparative Study with cyclosporine
16. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency
17. Optimization of methods for aspartate aminotransferase and alanine aminotransferase
18. Direct spectrophotometry of total bile acids in serum
19. Enzymatic assay for glutathione
20. Bile flow
21. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione
22. Cyclosporine
23. Cholestatic effect of cyclosporine in the rat
24. Inhibition of bile salt transport by cyclosporine A in rat liver plasma membrane vesicles
25. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver
26. Unidirectional pathway of vesicular cholesterol transport
27. Bile salt biosynthesis
28. Cyclosporine A hepatotoxicity: Effect of prolonged treatment with cyclosporine on biliary lipid secretion in the rat
29. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat